Takeda’s dengue vaccine QDENGA approved for use in EU
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Subscribe To Our Newsletter & Stay Updated